Skip to main content
Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity

Fig. 5

Toxicity study after single-dosage. a Body weight change after single-dosage with DOX, FRRG-DOX or F68-FDOX. b The serological examination on day 9 after single-dosage with DOX, FRRG-DOX or F68-FDOX. c The complete blood count (CBC) analyses on day 9 after single-dosage with DOX, FRRG-DOX or F68-FDOX. d) Major organ tissues stained with H&E on day 9 after single-dosage with DOX, FRRG-DOX or F68-FDOX. Significance was determined by Tukey−Kramer post-hoc test

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us